Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, has announced the pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of US$17.50 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 822,557 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately US$96 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters’ option. The offering is expected to close on or about January 22, 2021, subject to customary closing conditions.
Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by Boston partner Peter Handrinos and New York partner Nathan Ajiashvili, with associates Jennifer Yoon, Ryan Gold, and MacLane Taggart.